SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma

Summary

The purpose of this study is to evaluate the efficacy and safety of first-line with recombinant anti-EGFR monoclonal antibody#SCT200#and standard chemotherapy in patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

Timeline

Start

2019-05-21

Primary completion

2020-06-30

Completion

2021-07-01

Drugs

Indications